Table 2.

Determination of aiphanol IC₅₀ in different tumor cells and stromal cells

Types	IC50 (μM)	24 h	48 h	72 h
Gastric cancer	AGS	78.83	46.81	33.32
Lung cancer	PG	223.2	35.28	20.66
	A549	53.8	27.55	23.19
	H1299	198.58	93.03	62
	GLC-82	204.33	160.1	41.29
Colon cancer	LoVo	192.6	85.91	34.18
	SW620	58.28	29.94	23.25
	HCT116	49.35	24.63	16.54
	HT29	53.13	15.93	8.34
	DLD1	209	31	25.02
	SW480	154.21	76.17	37.47
	MC38	195.54	123.6	83.19
Liver cancer	SMMC-7221	93.45	66.48	41.54
	BEL-7402	74.77	28.21	23.89
	HepG2	97.44	49.71	31.35
Bladder cancer	T24	92.88	30.27	20.39
	EJ	51.01	29.81	17.09
Pancreatic cancer	PANC1	103.56	75	33.96
	SW1990	92.45	50	41.27
Esophagus cancer	EC9706	46.47	25.66	23.37
	KYSE70	140	39.9	23.86
Breast cancer	MCF7	97.28	55.59	35.46
	BICR	43.06	27.91	18.17
	MDA-MB-231	48.8	29.73	18.45
	4T1	173.11	152.44	93.89
Nasopharyngeal cancer	CNE	49.78	36.52	32.1
Cervical cancer	HeLa	89.86	41.27	37.38
Blood vessel	HUVEC	89.57	54.95	39.88
	HMEC	92.73	55.72	34.98
Lymphatic vessel	HDLEC	94.55	42.71	31.6